blog-icon

Clinical research blog

Explore our blog for insights into the big questions in precision medicine and clinical research.

AI in precision medicine is skipping a step: Checking its data

Most discussion of AI in precision medicine centers on what models can do, such as nominating drug targets or interpreting variants. Much less attention goes to...
Continue reading

From N-of-1 to N-of-many: What haplotype-matched ASOs mean for rare disease trials

A new study published in The American Journal of Human Genetics suggests that individualized genetic therapies could eventually treat larger groups of patients ...
Continue reading

Podcast recap: Joe Volpe on how blood biomarkers are changing neurology

Neurologists have long diagnosed brain disease through clinical impression, experience, and imaging. Blood biomarkers now add a different kind of evidence: a sc...
Continue reading

FDA's new genome editing guidance: Why patient identification matters earlier in development

The FDA's draft guidance on individualized human genome editing products, issued on 27 October 2026, proposes a pathway that could allow a single biologics lice...
Continue reading

What BEAM-301 reveals about the next challenge in precision medicine trials

Beam Therapeutics' early clinical results highlight the promise of mutation-specific therapies. But as treatments become more genetically targeted, they also ra...
Continue reading

FDA's rare disease framework could center patient identification

An FDA notice seeking public input is under review at the Office of Management and Budget, according to a Citeline report on October 12, 2026. The notice sugges...
Continue reading

AATD gene editing race hinges on patient identification

In September 2026, three in vivo gene editing programs reported progress against the same rare disease, aimed at the same mutation. On September 7, YolTech repo...
Continue reading

Genetic eligibility shows up earlier in the pipeline than most plans assume

During enrollment planning, genetic eligibility is often treated as a therapy area question, settled once a program knows which organ system it targets. Genetic...
Continue reading

Autoimmune cell therapy pauses expose stratification gaps

Novartis and Bristol Myers Squibb have paused multiple trials of their autoimmune cell therapies following inflammatory side effects. Novartis placed holds on i...
Continue reading

FDA draft guidance expands single-trial effectiveness pathway

In June 2026, the FDA released a revised draft guidance, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, that clarif...
Continue reading